Peripheral blood lymphoid subsets and long-term clinical course of kidney recipients: A longitudinal study

Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation

“…Although no acute rejection episodes with either regimen were seen in our patients, it is important to note that the slower recovery of CD3 + and CD3 + CD4 + cells with Thymo 1.5 mg/kg/day regimen might imply additional immunological benefit and thus, possibly better long-term graft survival. Others have shown that recovery of these T-cell subsets early post-transplant may be related with poorer long-term graft function [23].…”

Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation

“…Furthermore, AAR triplet analysis (HLA Matchmaker computer algorithm) can explain or predict the development of post-transplant antibodies in kidney allograft recipients [46,50] . Subsequent analyses of patients' antibodies and HLA-specific monoclonal antibodies have revealed that each HLA consists of structurally defined "eplets" that represent epitopes comprised of the AARs within a 3 Å-5 Å radius of the surface of the molecule [48,10,122] . An example of such analysis is presented in Figure 9, Figure 10 and Table 2.…”

“…In solid organ transplantations of the kidney, heart, lung, and pancreas graft outcomes critically depend on the degree of HLA matching between the donor and recipient [9][10][11][12][13][14][15][16][17] . The cellular components of the allogeneic immune response to the transplanted tissue play a key role in this matching and the contribution of antibodies should not be underestimated [18][19][20][21][22] .…”

Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation

“…In kidney transplantation, graft outcomes critically depend on the degree of HLA matching between the donor and recipient (Abe et al, 1997;Akalin & Pascual, 2006;Balan et al, 2008;Bas et al, 1998;Claas et al, 2005;Scornik et al, 1992;Takemoto et al, 2004;Terasaki 2003;). Although the cellular component of the allogenic immune response to the transplanted tissue plays a key role in this matching, the contribution of antibodies should not be underestimated Bartel et al, 2007;Stegall et al, 2009;Sumitran-Holgersson, 2001;Vasilescu et al, 2004;Zeevi et al, 2009).…”

“…More recently, it was reported that sensitized TCs require different DS regimens to reduce DSA levels, including varying the IVIG dose and the number of PP cycles Thielke et al, 2005;Ferrari-Lacraz et al, 2006;Glotz et al, 2004;Rogers et al, 2011). Subsequent studies have demonstrated that susceptibility to IVIG/PP DS depends on immunoregulatory mechanisms, such as polymorphisms in cytokine genes, the frequency of regulatory cells, and hormonal backgrounds (Figure 7) (Glotz et al, 2004;Rogers et al, 2011;Zachary et al, 2003;Bas et al, 1998;Di Genova et al, 2006, 2010Jiang & Lechler, 2003, Amu et al, 2007Anderson et al, 2000;Hill & Sarvetnick, 2002;Kalil et al, 1989;Stasi et al, 2008;Stastny P et al, 2006;Yoo et al, 1995). Furthermore, the efficacy of DS has been reported to be different for DSAs and third-party HLA antibodies.…”